Cancer Breakthroughs: Veracyte’s Decipher Tests and GRID Tool at ASCO GU
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) highlight the clinical utility of its Decipher Prostate and Decipher Bladder tests in guiding treatment for prostate and bladder cancer patients. Additionally, the findings showcase how Veracyte’s Decipher GRID (Genomic Resource for Intelligent Discovery) research tool is providing valuable insights that could drive future advancements in personalized cancer care. These results were shared through 17 Decipher-focused abstracts at the conference and a newly published paper in Annals of Oncology.
Veracyte, Inc., a leading cancer diagnostics company, presented new data at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU), showcasing the impact of its Decipher Prostate and Decipher Bladder tests in guiding treatment for prostate and bladder cancer patients. The findings also highlighted the potential of Veracyte’s Decipher GRID (Genomic Resource for Intelligent Discovery) research tool to further advance personalized cancer care. The data, presented across 17 Decipher-focused abstracts and a new publication in Annals of Oncology, underline the clinical utility of these genomic tests in improving patient outcomes and advancing cancer research.
Dr. Elai Davicioni, Veracyte’s Medical Director for Urology, emphasized the significance of these findings, noting, “The breadth and depth of Decipher-focused data presented at the ASCO GU Symposium reinforce the widespread impact our Decipher tests are having on clinical care, as well as on research into the molecular underpinnings of prostate and bladder cancers. We are grateful for our ongoing collaborations with leading clinician-researchers, which enable us to continue driving innovation that can further help patients.”
Key Findings from ASCO GU Symposium:
- Decipher Score as a Predictor of Response to Treatment Intensification in Prostate Cancer
Presented by Dr. Alan Pollack from the University of Miami Health System, this study analyzed data from the NRG Oncology-RTOG 0534 (SPPORT) Phase III randomized post-prostatectomy salvage radiotherapy trial. The study found that the Decipher Prostate Genomic Classifier could help identify patients who would benefit from intensifying treatment, particularly through the addition of pelvic nodal radiation. In a post-hoc analysis of 709 patients, those with high Decipher Prostate scores showed greater benefits from adding pelvic lymph node radiation and short-term androgen deprivation therapy (STADT) to prostate bed radiation therapy (PBRT). These findings demonstrate how the Decipher Prostate test can guide decision-making in prostate cancer treatment, especially when deciding on radiation therapy intensification, which can have additional side effects. - Molecular Subtyping for Bladder Cancer Outcomes
Dr. Yair Lotan from UT Southwestern Medical Center presented research that showed how the Decipher Bladder Genomic Subtyping Classifier can identify patients with less aggressive bladder cancer based on molecular subtype. The study focused on 226 patients with high-grade, clinically organ-confined bladder cancer who underwent radical cystectomy without neoadjuvant therapy. Results showed that patients with the luminal favorable bladder cancer subtype had a significantly lower risk of disease upstaging and better overall survival. This finding suggests that Decipher Bladder test results could assist physicians in identifying patients who may not need treatment intensification, ultimately leading to more personalized care and avoiding unnecessary aggressive treatments. - PORTOS Genomic Signature and Radiation Therapy in Prostate Cancer
In an oral presentation by Dr. Shuang Zhao from the University of Wisconsin-Madison, findings from the validation of the PORTOS (Post-Operative Radiation Therapy Outcomes Score) genomic signature were presented. This study, published in Annals of Oncology, demonstrated that the PORTOS signature, developed using the Decipher GRID research tool, can predict which prostate cancer patients will benefit from dose-escalated radiation therapy. Data from two Phase III randomized trials—the SAKK 09/10 and NRG Oncology/RTOG 0126—showed that patients with higher PORTOS scores experienced greater benefits from higher doses of salvage and definitive radiotherapy. This research highlights the potential of genomic signatures in refining radiation therapy strategies, improving patient outcomes, and offering a more personalized approach to treatment.
Dr. Zhao commented, “Physicians are currently limited in their tools for determining which patients with prostate cancer will benefit from dose-escalated radiation therapy. Our findings, derived from two Phase 3, randomized trials, suggest that the research-based PORTOS signature has the potential to be a useful clinical tool to help inform important radiation treatment decisions for patients following a prostate cancer diagnosis or those experiencing biochemical recurrence.”
Veracyte’s Commitment to Innovation
Veracyte continues to drive innovation in cancer diagnostics, particularly in the field of genitourinary cancers. The Decipher tests are helping clinicians make more informed decisions, offering insights into treatment response, cancer aggression, and radiation therapy benefits. The company’s ongoing collaborations with clinician-researchers and the integration of genomic tools like Decipher GRID ensure that Veracyte remains at the forefront of personalized cancer care.
As Dr. Davicioni stated, “We are grateful for our ongoing collaborations with leading clinician-researchers, which are enabling us to continue driving innovation that can further help patients.” The new data presented at ASCO GU underscores the significant role these tests and tools play in advancing both clinical care and cancer research.
